Active, not recruiting
A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Respiratory Syncytial Virus Disease
NCT07220109
- Conditions
- Infections, Mononegavirales Infections, Paramyxoviridae Infections, +4 more
- Locations
-
- GSK Investigational Site Beijing, Beijing Municipality, China
- GSK Investigational Site Xiangtan, Hunan, China
- GSK Investigational Site Nanjing, Jiangsu, China
- GSK Investigational Site Chengdu, Sichuan, China